Skip to content
Triangle logo TriangleGet started
← Full study record

NCT00551070 · BASELINE

Baseline characteristics

Selumetinib Sulfate in Treating Woman With Recurrent Low-Grade Ovarian Cancer or Peritoneum Cancer · Source last updated 2020-12-03

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

denoms
  1. counts
    1. group Id
      BG000
      value
      52
    units
    Participants
groups
  1. description
    AZD6244 (NSC #748727) 100 mg orally BID until disease progression or adverse effects prohibit further therapy (1 cycle =28 days)
    id
    BG000
    title
    AZD6244
measures
  1. classes
    1. categories
      1. measurements
        1. group Id
          BG000
          value
          3
      title
      20-29 years
    2. categories
      1. measurements
        1. group Id
          BG000
          value
          11
      title
      30-39 years
    3. categories
      1. measurements
        1. group Id
          BG000
          value
          8
      title
      40-49 years
    4. categories
      1. measurements
        1. group Id
          BG000
          value
          17
      title
      50-59 years
    5. categories
      1. measurements
        1. group Id
          BG000
          value
          9
      title
      60-69 years
    6. categories
      1. measurements
        1. group Id
          BG000
          value
          4
      title
      70-79 years
    7. categories
      1. measurements
        1. group Id
          BG000
          value
          0
      title
      80-89 years
    param Type
    NUMBER
    title
    Age, Customized
    unit Of Measure
    participants
  2. classes
    1. categories
      1. measurements
        1. group Id
          BG000
          value
          52
        title
        Female
      2. measurements
        1. group Id
          BG000
          value
          0
        title
        Male
    param Type
    COUNT_OF_PARTICIPANTS
    title
    Sex: Female, Male
    unit Of Measure
    Participants
population Description
Eligible and treated patients.
Complete source fields
denoms
  1. counts
    1. group Id
      BG000
      value
      52
    units
    Participants
groups
  1. description
    AZD6244 (NSC #748727) 100 mg orally BID until disease progression or adverse effects prohibit further therapy (1 cycle =28 days)
    id
    BG000
    title
    AZD6244
measures
  1. classes
    1. categories
      1. measurements
        1. group Id
          BG000
          value
          3
      title
      20-29 years
    2. categories
      1. measurements
        1. group Id
          BG000
          value
          11
      title
      30-39 years
    3. categories
      1. measurements
        1. group Id
          BG000
          value
          8
      title
      40-49 years
    4. categories
      1. measurements
        1. group Id
          BG000
          value
          17
      title
      50-59 years
    5. categories
      1. measurements
        1. group Id
          BG000
          value
          9
      title
      60-69 years
    6. categories
      1. measurements
        1. group Id
          BG000
          value
          4
      title
      70-79 years
    7. categories
      1. measurements
        1. group Id
          BG000
          value
          0
      title
      80-89 years
    param Type
    NUMBER
    title
    Age, Customized
    unit Of Measure
    participants
  2. classes
    1. categories
      1. measurements
        1. group Id
          BG000
          value
          52
        title
        Female
      2. measurements
        1. group Id
          BG000
          value
          0
        title
        Male
    param Type
    COUNT_OF_PARTICIPANTS
    title
    Sex: Female, Male
    unit Of Measure
    Participants
population Description
Eligible and treated patients.

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice